MX342548B - Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. - Google Patents

Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.

Info

Publication number
MX342548B
MX342548B MX2012003310A MX2012003310A MX342548B MX 342548 B MX342548 B MX 342548B MX 2012003310 A MX2012003310 A MX 2012003310A MX 2012003310 A MX2012003310 A MX 2012003310A MX 342548 B MX342548 B MX 342548B
Authority
MX
Mexico
Prior art keywords
opioid
opioid receptor
compound
gastrointestinal tract
receptor antagonist
Prior art date
Application number
MX2012003310A
Other languages
English (en)
Spanish (es)
Other versions
MX2012003310A (es
Inventor
M Woodward Richard
Original Assignee
Merck Sharp & Dohme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342548(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp * filed Critical Merck Sharp & Dohme Corp *
Publication of MX2012003310A publication Critical patent/MX2012003310A/es
Publication of MX342548B publication Critical patent/MX342548B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2012003310A 2009-09-18 2010-09-17 Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. MX342548B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (2)

Publication Number Publication Date
MX2012003310A MX2012003310A (es) 2012-07-17
MX342548B true MX342548B (es) 2016-10-04

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003310A MX342548B (es) 2009-09-18 2010-09-17 Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN102695508A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760880B1 (en) 2012-12-28 2015-07-08 Instytut Medycyny Doswiadczalnej I Klinicznej Peptidomimetics and their application
AR108535A1 (es) 2016-05-20 2018-08-29 Esteve Labor Dr Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CA3124115A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ES2188657T3 (es) 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
ES2402749T3 (es) * 2007-12-11 2013-05-08 Theravance, Inc. Derivados de 3-carboxipropil-aminotetralina como antagonistas del receptor de opioide mu
TWI449685B (zh) * 2008-12-10 2014-08-21 Theravance Inc ３－羧基丙基－胺基四氫化萘化合物之結晶型
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose

Also Published As

Publication number Publication date
JP5797655B2 (ja) 2015-10-21
ZA201201954B (en) 2012-11-28
NZ598783A (en) 2013-07-26
BR112012006069A2 (pt) 2016-03-29
IL218679A0 (en) 2012-05-31
CO6531453A2 (es) 2012-09-28
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
RU2561873C2 (ru) 2015-09-10
KR20120092592A (ko) 2012-08-21
AU2010295464A1 (en) 2012-04-12
CA2774021A1 (en) 2011-03-24
CN104958298A (zh) 2015-10-07
TW201118084A (en) 2011-06-01
MX2012003310A (es) 2012-07-17
EP2477627A1 (en) 2012-07-25
CN102695508A (zh) 2012-09-26
EP2477627B1 (en) 2018-08-15
JP2013505260A (ja) 2013-02-14
HK1210959A1 (en) 2016-05-13
AU2010295464B2 (en) 2015-11-26
US20110071163A1 (en) 2011-03-24
BR112012006069A8 (pt) 2017-10-10
WO2011035142A1 (en) 2011-03-24
PE20120991A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MX2012004848A (es) Compuestos heterociclicos triciclicos.
NZ580963A (en) Compositions and methods for prophylaxis and treatment of addictions
MX2012011631A (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
MX361542B (es) Compuestos de morfinan.
NZ600379A (en) Morphinan derivatives for the treatment of drug overdose
WO2007056300A3 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2009011958A (es) Compuestos de morfina.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
WO2011020030A3 (en) Methods and compositions to prevent addiction
SI1765349T1 (sl) Opioidi za zdravljenje kronične obstrukcijske pljučne bolezni (KOPB)
MX2012014934A (es) Antagonistas de ciclohexilacetindinilo del receptor de la citocina quimioatrayente 2.
WO2010080756A3 (en) Harmine derivatives for reducing body weight
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
GB2477256A (en) Medicament and method of diagnosis
MX2012003310A (es) Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
WO2012012410A3 (en) Kappa opioid receptor agonists
WO2011044511A3 (en) Rage regulates rock activity in cardiovascular disease
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration